<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Biofrontera Ag — News on 6ix</title>
    <link>https://6ix.com/company/biofrontera-ag</link>
    <description>Latest news and press releases for Biofrontera Ag on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Thu, 23 Oct 2025 12:45:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/biofrontera-ag" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d6cb42beedb30cb6002366.webp</url>
      <title>Biofrontera Ag</title>
      <link>https://6ix.com/company/biofrontera-ag</link>
    </image>
    <item>
      <title>Biofrontera Inc. Closes Purchase of All Ameluz® and RhodoLED® US Assets from Biofrontera AG</title>
      <link>https://6ix.com/company/biofrontera-ag/news/biofrontera-inc-closes-purchase-of-all-ameluzr-and-rhodoledr-us-assets-from-biofrontera-ag</link>
      <guid isPermaLink="true">https://6ix.com/company/biofrontera-ag/news/biofrontera-inc-closes-purchase-of-all-ameluzr-and-rhodoledr-us-assets-from-biofrontera-ag</guid>
      <pubDate>Thu, 23 Oct 2025 12:45:00 GMT</pubDate>
      <description>Biofrontera Inc. acquires full U.S. rights to Ameluz® and RhodoLED®, including New Drug Application and associated patents, from former parent Biofrontera AG.New earnout structure reduces payment rate to 12%–15% of U.S. net sales from 25%–35%.Closing releases final $2.5 million of $11 million financing led by existing investors Rosalind Advisors and AIGH Capital Management, which is expected to fund Biofrontera Inc. to profitability. WOBURN, Mass., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Biofrontera I</description>
    </item>
    <item>
      <title>Biofrontera Inc. Reports Second Quarter 2025 Financial Results and Provides a Business Update</title>
      <link>https://6ix.com/company/biofrontera-ag/news/biofrontera-inc-reports-second-quarter-2025-financial-results-and-provides-a-business-update</link>
      <guid isPermaLink="true">https://6ix.com/company/biofrontera-ag/news/biofrontera-inc-reports-second-quarter-2025-financial-results-and-provides-a-business-update</guid>
      <pubDate>Wed, 13 Aug 2025 21:20:00 GMT</pubDate>
      <description>Woburn, MA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the &quot;Company&quot;), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy in dermatology, today reported financial results for the three and six months ended June 30, 2025 and provided a business update. Highlights from the first six months of 2025 included the following: Total revenues for the second quarter of 2025 were $9.0 million, a 15% increase from the same period</description>
    </item>
    <item>
      <title>Biofrontera Inc. Appoints George Jones as Chief Commercial Officer</title>
      <link>https://6ix.com/company/biofrontera-ag/news/biofrontera-inc-appoints-george-jones-as-chief-commercial-officer</link>
      <guid isPermaLink="true">https://6ix.com/company/biofrontera-ag/news/biofrontera-inc-appoints-george-jones-as-chief-commercial-officer</guid>
      <pubDate>Mon, 11 Aug 2025 20:25:00 GMT</pubDate>
      <description>Woburn, MA, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company focused on the development and commercialization of photodynamic therapy (PDT), today announced the appointment of George Jones as Chief Commercial Officer (CCO), starting August 25, 2025. In this role, Mr. Jones will oversee the Company’s commercial functions, including sales, marketing, and market access. He will report directly to CEO Dr. Hermann Luebbert. This strengthen</description>
    </item>
    <item>
      <title>Biofrontera Inc. Announces Major Restructuring of Relationship With Biofrontera AG Backed By $11 Million Investment</title>
      <link>https://6ix.com/company/biofrontera-ag/news/biofrontera-inc-announces-major-restructuring-of-relationship-with-biofrontera-ag-backed-by-dollar11-million-investment</link>
      <guid isPermaLink="true">https://6ix.com/company/biofrontera-ag/news/biofrontera-inc-announces-major-restructuring-of-relationship-with-biofrontera-ag-backed-by-dollar11-million-investment</guid>
      <pubDate>Mon, 30 Jun 2025 12:00:00 GMT</pubDate>
      <description>Biofrontera Inc. has signed an agreement to acquire all US assets related to Ameluz® and RhodoLED® including New Drug Application (NDA) and associated patents from Germany-based Biofrontera AG.Under their new agreement, the effective royalty rate paid by Biofrontera Inc. will be reduced to 12% (and 15% above revenue of $65 million) of net sales from 25% - 35% of net sales.This transaction, coupled with an $11 million financing led by existing investors, Rosalind Advisors and AIGH Capital Managem</description>
    </item>
  </channel>
</rss>